Slide 1: Annual General Meeting
For personal use only Annual General Meeting 31 October 2012 Dr. Marie Roskrow Chief Executive Officer ASX: PAB
Slide 2: Safe Harbour Statement
Safe Harbour Statement For personal use only The following material is for general information purposes only and is not to be relied upon for the making of an investment decision. Any investment in Patrys Limited ACN 123 055 363 (Patrys) is subject to investment risk including the possibility of los
Slide 3: Corporate Overview
Corporate Overview For personal use only KEY STATISTICS – 30 SEPTEMBER 2012 (AUD$) 2012 SHARE PERFORMANCE ASX Code PAB Current share price $0.038 Share Price A$ 52 Week High $0.06 52 Week Low $0.015 Shares on Issue 507,287,177 Market Capitalisation $19.3 m Average Daily Volume ~400,000 Shareholders
Slide 4: FY12 Capital Raisings
FY12 Capital Raisings For personal use only 2 December 2011 22 June 2012 Amount: $3.4m Amount: $2.8m Issue Price: 3 cents per share Issue Price: 2 cents per share Share Placement Method: Share Placement Method: & SPP Current cash position (Sept. 2012): $7m Runway to early 2014 4
Slide 5: FY12 Programme Overview I
FY12 Programme Overview I Patrys made significant progress in the clinic: Completed melanoma trial, prepared to For personal use only commence multiple myeloma trial PAT-SM6 Clinical: Phase 1 single-dose melanoma study completed Feb. 2012 Safe & well tolerated in all treated patients Detected pr
Slide 6: FY12 Programme Overview II
FY12 Programme Overview II For personal use only PAT-SC1 Preclinical: Out-licensing project underway (Japan & South Korea) Add. purification work ongoing with collaborators in Singapore Paper submitted for publication (clinical trial survival data) PAT-LM1 Preclinical: Commenced collaboratio
Slide 7: Multiple Myeloma - Opportunity
Multiple Myeloma - Opportunity A cancer of the plasma cells in bone marrow. These cells grow out of control and form For personal use only tumours in solid bone, cause damage to other organs Estimated to be more than 220,000 cases worldwide and incidence increasing 5 year survival of 29%. Desp
Slide 8: Multiple Myeloma - Pathology
Multiple Myeloma - Pathology For personal use only Abnormal plasma cells (myeloma Monoclonal gammopathy detected by cells) secrete lots of “useless” electrophoresis antibodies (M proteins) Myeloma cells crowd out other blood cells resulting in anaemia, thrombocytopenia (bleeding) and leucopeni
Slide 9: Multiple Myeloma - Presentation
Multiple Myeloma - Presentation For personal use only Bone disease and hypercalcemia 9
Slide 10: Multiple Myeloma - Presentation
Multiple Myeloma - Presentation For personal use only Evidence of bone marrow failure 10
Slide 11: Therapies for Multiple Myeloma
Therapies for Multiple Myeloma For personal use only Proteosome inhibitors Clinical studies Bortezomib (Velcade) Small molecules Carfilzomib (Kyprolis) Antibodies, peptides IMIDs Lanalidomid (Revlimid) Thalidomide Chemotherapeutics Melphalan Cisplatin Cyclophosphamide Dox
Slide 12: Antibodies in Clinical Trials for MM
Antibodies in Clinical Trials for MM For personal use only Daratumumab PAT-SM6 Elotuzumab GRP78 BHQ880 CD138 toxin- conjugated Antibodies in all stages of clinical development 12
Slide 13: PAT-SM6 Antibody & Target
PAT-SM6 Antibody & Target For personal use only PAT-SM6: IgM isotype, λ-light chain Isolated from stomach cancer patient Recombinantly expressed in PER.C6® Targets tumour specific epitope on GRP78 Binds also to oxidised LDL and VLDL Mode of Action: Internalisation upon binding of oxidise
Slide 14: Preclinical Data I – Multiple Myeloma
Preclinical Data I – Multiple Myeloma For personal use only Patient tissue sourced Isotype Control CD138 PAT-SM6 from 11 patients at primary diagnosis, 9 with MM1 relapsed disease and 4 healthy controls IHC staining on bone marrow sections show MM2 binding of PAT-SM6 in 20/20 MM patients (primar
Slide 15: Preclinical Data II – Multiple Myeloma
Preclinical Data II – Multiple Myeloma For personal use only PAT-SM6 mediates cytotoxicity to patient MM cells and MM cell lines by induction of apoptosis A 80 ** ** ** ** B 100 ** PI/LDS positive cells (%) PI/LDS positive cells (%) U266 INA-6 80 60 OPM-1 MM1S 60 40 40 ns 20 20 0 0 PAT-SM-6 [µg/ml
Slide 16: Preclinical Data III – Multiple Myeloma
Preclinical Data III – Multiple Myeloma For personal use only PAT-SM6 binds C1q and mediates complement deposition and activation on both cell lines and patient cells A B 1.5 PAT-SM6 Binding C1q Deposition Rituximab PAT-SM6 1.0 Control Anti-C1q without PAT-SM6 OD 450nm Isotype PAT-SM6 Anti-C1q wit
Slide 17: Phase I/IIa PAT-SM6 Multiple Myeloma Study Design
Phase I/IIa PAT-SM6 Multiple Myeloma Study Design For personal use only Screening Day -14 to -1 Treatment Day 1, 3, 8, 10 with PAT-SM6 Ambulatory visits on Day 15 and 22 After completion of Day 15: DSMB decision on dose escalation Serological staging Day 29 Day 36 ≥ PR* ≥ PR* SD or PD Treatment Trea
Slide 18: Possible Future Plans for PAT-SM6
Possible Future Plans for PAT-SM6 For personal use only Positive Phase I/IIa MM clinical trial data + existing positive Phase I melanoma data + extensive preclinical package: Option 1: Do a deal Out-license to major oncology company on WW basis Out-license but retain some rights / territories
Slide 19: Plans for 2013
Plans for 2013 For personal use only Execute PAT-SM6 Phase I/IIa open-label multi-dose multiple myeloma clinical trial Continue preclinical work with PAT-SM6 and multiple myeloma (animal models, drug combination studies) Expand external collaborations around all programmes to generate new data
Slide 20: For Further Information
For Further Information For personal use only Contact Details: Dr Marie Roskrow, Chief Executive Officer Mr Roger McPherson, Chief Financial Officer Ph: +61 3 9670 3273 Email: info@patrys.com Website: www.patrys.com 20